NLS Pharmaceutics Ltd. Warrant (NLSPW)

• Market cap: $49.6K
• 1 day: -19.07%
• 5 days: -20.71%
• 1 month: 2.61%
• 3 months: 248.89%
• 6 months: -10.29%
• Year to date: 30.83%
• 1 year: -70.93%
• 5 years: -97.96%
• 10 years: -97.96%
• Sector: Healthcare
• Industry: Biotechnology

About: NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Employees: 1

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.8% less ownership

Funds ownership: 1.03% [Q4 2024] → 0.22% (-0.8%) [Q1 2025]

40% less funds holding

Funds holding: 5 [Q4 2024] → 3 (-2) [Q1 2025]

78% less capital invested

Capital invested by funds: $5.17K [Q4 2024] → $1.14K (-$4.03K) [Q1 2025]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2